| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 965 | 2018 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 617* | 2019 |
| Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study G Salles, J Duell, EG Barca, O Tournilhac, W Jurczak, AM Liberati, Z Nagy, ... The Lancet Oncology 21 (7), 978-988, 2020 | 461 | 2020 |
| Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial MV Mateos, M Cavo, J Blade, MA Dimopoulos, K Suzuki, A Jakubowiak, ... The Lancet 395 (10218), 132-141, 2020 | 393 | 2020 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 342 | 2018 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 249 | 2021 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 242 | 2019 |
| Effect of gypsum on proliferation and differentiation of MC3T3-E1 mouse osteoblastic cells Á Lazáry, B Balla, JP Kósa, K Bácsi, Z Nagy, I Takács, PP Varga, G Speer, ... Biomaterials 28 (3), 393-399, 2007 | 135 | 2007 |
| Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma J Duell, KJ Maddocks, E González-Barca, W Jurczak, AM Liberati, ... haematologica 106 (9), 2417, 2021 | 132 | 2021 |
| The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria A Röth, J Nishimura, Z Nagy, J Gaàl-Weisinger, J Panse, SS Yoon, ... Blood, The Journal of the American Society of Hematology 135 (12), 912-920, 2020 | 103 | 2020 |
| Prävention der Kortikosteroid-induzierten Osteoporose durch Alfacalcidol P Lakatos, Z Nagy, L Kiss, C Horvath, I Takacs, J Foldes, G Speer, ... Zeitschrift für Rheumatologie 59, I48-I52, 2000 | 95 | 2000 |
| FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic … M Spina, Z Nagy, JM Ribera, M Federico, I Aurer, K Jordan, G Borsaru, ... Annals of oncology 26 (10), 2155-2161, 2015 | 84 | 2015 |
| Comparing the trueness of seven intraoral scanners and a physical impression on dentate human maxilla by a novel method Z Nagy, B Simon, A Mennito, Z Evans, W Renne, J Vág BMC Oral Health 20, 1-10, 2020 | 78 | 2020 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 74 | 2023 |
| Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism P Lakatos, J Foldes, Z Nagy, I Takacs, G Speer, C Horvath, S Mohan, ... Thyroid 10 (5), 417-423, 2000 | 70 | 2000 |
| Rho and Rho Kinase Are Involved in Parathyroid Hormone‐Stimulated Protein Kinase C α Translocation and IL‐6 Promoter Activity in Osteoblastic Cells JM Radeff, Z Nagy, PH Stern Journal of bone and mineral research 19 (11), 1882-1891, 2004 | 58 | 2004 |
| Different gene expression patterns in the bone tissue of aging postmenopausal osteoporotic and non-osteoporotic women B Balla, JP Kósa, J Kiss, A Borsy, J Podani, I Takács, A Lazáry, Z Nagy, ... Calcified tissue international 82, 12-26, 2008 | 54 | 2008 |
| Hungarian consensus regarding the role of vitamin D in the prevention and treatment of diseases I Takács, I Benkő, E Toldy, N Wikonkál, L Szekeres, E Bodolay, E Kiss, ... Orvosi hetilap 153, 5-26, 2012 | 52 | 2012 |
| Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study FH Schjesvold, MA Dimopoulos, S Delimpasi, P Robak, D Coriu, ... The Lancet Haematology 9 (2), e98-e110, 2022 | 43 | 2022 |
| CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells JP Kósa, P Horváth, J Wölfling, D Kovács, B Balla, P Mátyus, E Horváth, ... World journal of gastroenterology: WJG 19 (17), 2621, 2013 | 43 | 2013 |
